LifeSci Advisors Initiates Coverage of Cancer Genetics, Inc.
April 01 2014 - 9:00AM
Marketwired
LifeSci Advisors Initiates Coverage of Cancer Genetics, Inc.
Strong Portfolio of Unique Genomic Diagnostic Tests for
Personalized Medicine in Oncology; Consistent Revenue and Gross
Profit Growth; $6.6 Million in 2013 Revenue; Report Available for
Download at
http://www.lifesciadvisors.com/clients/cancergenetics/
NEW YORK, NY--(Marketwired - Apr 1, 2014) - LifeSci Advisors,
LLC, a leading provider of investment research and investor
relations services in the life sciences sector, today announced
that it has initiated coverage of Cancer Genetics, Inc. (NASDAQ:
CGIX), a diagnostics company developing genomic-based oncology
tests and services to enhance disease management and patient
outcomes. The Company offers a wide-range of proprietary and
non-proprietary tests to support patients during all aspects of
their care, from initial diagnosis to prognosis, and determination
of optimal treatment options. Oncology is moving towards
categorizing cancers by their molecular signature rather than the
location in the body, and there is a continuing need for wider
access to diagnostic toolkits. Cancer Genetics collaborates with
leading research institutions for biomarker development, with
community hospitals to improve patient care, and with biotechnology
and pharmaceutical companies to provide clinical trial
services.
"Cancer Genetics couples its expertise identifying genetic
aberrations with recommendations for patient prognosis and
treatment, generating a personalized therapeutic plan for each
patient," said Andrew I. McDonald, Ph.D., Founding Partner at
LifeSci Advisors. "This level of focus on the patient has led to
key partnerships with Gilead and Roche, and sets the stage for
continued integration into the pursuit of personalized medicine in
oncology."
Cancer Genetics has five unique tests that are approved by New
York State and Clinical Laboratory Improvement Amendments (CLIA)
for leukemia, lymphomas, renal and cervical cancer. Mature B-cell
Neoplasm Array (MatBA®) is a genomic hybridization array for the
diagnosis and prognosis of non-Hodgkin lymphomas. UroGenRA™ is a
genomic hybridization array for the classification of urogenital
cancers, and FISH-based HPV-Associated Cancer Test (FHACT™) is a
platform for HPV-associated cervical cancer screening. Additional
indications are being pursued for each platform.
Cancer Genetics has deals in place with Gilead Sciences, Inc.
and Roche Servicios S.A., a Costa Rica-based subsidiary of Roche.
The partnerships are a validation of the Cancer Genetics' ability
to secure the necessary relationships to become the market leader
in diagnostics. Additionally, Cancer Genetics continues to invest
in developing further technology by leveraging next-generation
sequencing in a joint venture with Mayo Clinic that is focused on
developing panels for oncology indications in lung cancer,
follicular lymphoma, and multiple myeloma.
In a 35 page Initiation Report by LifeSci Advisors, we explain
the products and services offered by Cancer Genetics and how the
Company intends to continue expanding revenues. The report
discusses the three proprietary technology platforms and the
indications they target. We also explore the market potential and
competitive landscape for molecular diagnostics going forward.
Dr. McDonald's full Initiation Report is available to download
at no cost at the LifeSci Advisors website,
www.lifesciadvisors.com. In addition to this Initiation
Report, LifeSci Advisors will also provide ongoing coverage and
event-based research updates on the Company as developments
occur.
The LifeSci Advisors research team is led by Dr. Andrew I.
McDonald, an industry veteran with more than 15 years of healthcare
industry experience. Prior to co-founding LSA, Dr. McDonald
was the Senior Biotechnology Analyst at Great Point Partners, a
leading health care investment firm with over $500 million under
management. Before Great Point, he was Co-Head of Healthcare
Research and Lead Biotechnology Analyst at ThinkEquity Partners, a
boutique investment banking firm focused on growth
companies. Dr. McDonald holds a Ph.D. in organic chemistry
from the University of California, Irvine, and, earlier in his
career, worked as a medicinal chemist at both Pfizer and
Cytokinetics.
About LifeSci
Advisors:
LifeSci Advisors (LSA) is a leading research firm and
communications consultancy dedicated to the life sciences industry.
The firm provides strategic counsel, customized marketing
communications, comprehensive research reports and investor
relations services to companies that specialize in the discovery,
development and commercialization of drugs, drug delivery systems,
medical devices and diagnostics. To learn more about LSA,
visit the company's website, www.lifesciadvisors.com.
Important
Disclosures:
The research report described in this press release is not
intended as an offering, recommendation, or a solicitation of an
offer to buy or sell securities. The securities discussed in
LSA research reports may be unsuitable for some investors depending
on their specific investment objectives, financial status, risk
profile, or particular needs. Investors should consider LSA reports
as only a single factor in making their investment decisions and
should not rely solely on these reports in evaluating whether or
not to buy or sell the securities of the subject
company. LifeSci Advisors has been compensated by the company
that is the subject of the report described and future research
reports, investor relations services, and general consulting
services. Please read each report's full disclosures and analyst
background on the LSA website, www.lifesciadvisors.com, before
investing. LifeSci Advisors is not a registered investment
adviser or broker-dealer.
Forward-looking
statements:
This press release contains forward-looking statements subject
to risks and uncertainties that could cause actual results to
differ materially from those projected. These forward-looking
statements represent LSA's judgment as of the date of this release.
LifeSci Advisors disclaims, however, any intent or obligation to
update these forward-looking statements.
Media Contact: Michael Rice Phone: (646) 597-6979 Email:
mrice@lifesciadvisors.com
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Jul 2023 to Jul 2024